预约演示
更新于：2026-10-23
Famciclovir
泛昔洛韦
更新于：2026-10-23
概要
基本信息
药物类型 小分子化药 |
别名 2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate、9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine、acetic acid 2-acetoxymethyl-4-(2-amino-purin-9-yl)-butyl ester + [17] |
作用方式 抑制剂 |
作用机制 UL30抑制剂(人单纯疱疹病毒1型DNA聚合酶抑制剂)、UL54抑制剂(人单纯疱疹病毒5型DNA聚合酶抑制剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H19N5O4 |
InChIKeyGGXKWVWZWMLJEH-UHFFFAOYSA-N |
CAS号104227-87-4 |
关联
34
项与 泛昔洛韦 相关的临床试验NCT06798662
Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain: a Prospective, Randomized, Controlled, Triple-blind Trial
CTR20243063
泛昔洛韦片在中国健康受试者中空腹和餐后状态下的单剂量、随机、开放、两周期、两序列、交叉设计的生物等效性试验。
ChiCTR2400086204
Clinical study of dorsal root ganglion platelet-rich plasma injections in the treatment of herpes zoster neuralgia
100 项与 泛昔洛韦 相关的临床结果
登录后查看更多信息
100 项与 泛昔洛韦 相关的转化医学
登录后查看更多信息
100 项与 泛昔洛韦 相关的专利（医药）
登录后查看更多信息
1,220
项与 泛昔洛韦 相关的文献（医药）2026-12-31Virulence
Immunogenicity evaluation of recombinant rabies virus-vectored multivalent vaccines expressing feline calicivirus VP1 and feline herpesvirus 1 gB/gD genes
Article
作者: Chen, Nuan ; Guo, Xiaofeng ; Li, Xiaolong ; Luo, Jun ; Xie, Wanxing ; Wang, Yueze ; Liang, Yinyi ; He, Hongling ; Huang, Shile ; Zhao, Songze ; Wang, Yang ; Xin, Lerong ; Wang, Jiahao
Feline calicivirus (FCV) and feline herpesvirus 1 (FHV-1) are major pathogens threatening feline health, and prophylactic immunity remains the primary preventive approach. To develop a safe and effective multivalent vaccine against the two viruses, two recombinant rabies virus (RABV) vaccines expressing the FCV VP1 and FHV-1 gB/gD genes were constructed. The exogenous genes showed stable inheritance following serial viral passages, and the recombinant RABVs exhibited growth kinetics comparable to the parental strain, with a delayed peak titer. After verifying the viral pathogenicity, the recombinant RABV vaccines elicited specific IgG antibodies against VP1, gB, and gD, as well as neutralizing antibodies against FCV, FHV-1, and RABV in mice. Immunized mice were also protected against lethal RABV challenge. In cats, the vaccines induced neutralizing antibodies against the three pathogens, and immunized cats showed milder clinical signs and less severe histopathological lesions following FHV-1 and FCV challenge. Collectively, these findings indicate that the two recombinant vaccines induce robust humoral immune responses against FCV, FHV-1, and RABV in both mice and cats and confer protection against viral challenges.
2026-10-01ANTIVIRAL RESEARCH
Susceptibility of clinical isolates, laboratory-adapted and drug-resistant herpes simplex virus strains to helicase-primase inhibitor adibelivir (IM-250) and its synergy in combination therapy with acyclovir, penciclovir and foscarnet
Article
作者: Pérez-Osorio, Ailyn C ; Hagmaier, Timo ; Zhu, Haiying ; Gege, Christian ; Huzly, Daniela ; Madarampalli, Bhanupriya ; Kleymann, Gerald ; Jerome, Keith R ; Pretzsch, Nathalie ; Elis, Julia ; Falcone, Valeria
Herpes simplex virus (HSV) infections are widespread and cause a significant global health burden. Clinical manifestations range from herpes labialis and genital herpes to life-threatening herpes simplex encephalitis or neonatal herpes. Current treatment relies on nucleoside analogs such as acyclovir, valacyclovir or famciclovir. The emergence of resistance to these drugs is of concern in transplant recipients and immunocompromised patients. Next-generation helicase-primase inhibitors are under clinical development to provide more efficacious treatments and address resistance to current therapies. Adibelivir (IM-250) is a potent HSV helicase-primase inhibitor (HPI) with nanomolar activity against both HSV1 and HSV2. In the present study, we assessed the susceptibility of more than 50 clinical isolates and laboratory strains against adibelivir. Across all strains tested, adibelivir inhibited HSV replication in cell culture with mean EC50 values of 21 nM (HSV1) and 35 nM (HSV2), compared to up to 42-fold higher EC50 values for acyclovir (883 nM for HSV1 and 1456 nM for HSV2). No preexisting variants with a lack of susceptibility were identified. Furthermore, no cross-resistance was observed between nucleoside analogs and HPIs and finally, the antiviral activity depended on serum concentration and infectious dose. Collectively, these data establish the baseline susceptibility profile of HSV clinical isolates to adibelivir prior to its broader clinical introduction. Adibelivir retains activity against nucleoside-resistant HSV strains and exhibits synergistic antiviral effects when combined with acyclovir, penciclovir and foscarnet in vitro. These results support clinical evaluation of adibelivir as a therapeutic option for HSV infections and as a candidate for combination therapy.
2026-09-01Food and Environmental Virology
Ultrasound-Treated Ethanolic Extracts of Endemic Mount Ida Plants (Sideritis trojana and Hypericum kazdaghensis) Show Antiviral and Antibacterial Potential Against Norovirus Surrogates and Foodborne Bacteria
Article
作者: İpek, Dilvin ; Sánchez, Gloria ; Tuncel, Necati Barış ; Falcó, Irene
Human noroviruses and persistent bacterial pathogens remain major food-safety concerns. This screening study compared 40% (v/v) ethanolic extracts (EE) and ultrasound-treated ethanolic extracts (UTE) of the endemic Mount Ida plants Sideritis trojana Ehrend. and Hypericum kazdaghensis Gemici & Leblebici. Feline calicivirus (FCV) and murine norovirus (MNV) served as cultivable human-norovirus surrogates; four reference bacteria were examined by disc diffusion. Ultrasound treatment was associated with higher measured total phenolic content (approximately 2.2- to 3.8-fold) and antioxidant capacity (approximately 1.9- to 2.3-fold) than EE. The largest reduction was 4.71 log10 TCID50/mL for H. kazdaghensis-UTE against FCV after overnight exposure. For MNV, the largest reduction was 2.42 log10 TCID50/mL for S. trojana-EE after overnight exposure. Inhibition-zone diameters ranged from 6.25 to 11.75 mm, including the 6-mm disc. FRhK-4 viability ranged from approximately 56% to 100% across the tested conditions, precluding a general claim of low cytotoxicity. The results provide preliminary, surrogate- and assay-specific evidence of antiviral and antibacterial activity. Because solvent-only and positive controls were not included, causal attribution to plant constituents and comparison with established antimicrobials are not possible. Confirmatory controlled assays are required before practical food-safety use can be proposed.
100 项与 泛昔洛韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 生殖器疱疹 | 美国 | 2009-12-24 | |
| 唇疱疹 | 美国 | 2009-12-24 | |
| 单纯疱疹 | 美国 | 1994-06-29 | |
| 带状疱疹 | 美国 | 1994-06-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 水痘 | 临床3期 | 美国 | 2005-07-01 | |
| 水痘 | 临床3期 | 哥斯达黎加 | 2005-07-01 | |
| 水痘 | 临床3期 | 危地马拉 | 2005-07-01 | |
| 水痘 | 临床3期 | 巴拿马 | 2005-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 多发性硬化症 Epstein-Barr virus (EBV) | 30 | 醖壓繭範範簾膚廠鬱願(築範衊糧觸襯鹽鏇網遞) = 膚膚願餘襯膚醖獵襯獵 餘鑰壓網獵壓繭糧鹽窪 (醖膚淵鏇選鹹襯壓繭衊 ) | - | 2023-09-30 | ||
临床2/3期 | 53 | 淵構鑰餘觸築蓋繭蓋積(簾齋範觸襯衊構壓鏇餘) = 餘衊鏇淵積醖觸積觸鹽 壓觸蓋選憲願遞蓋願築 (膚鬱鹽醖範襯顧範夢鬱, 糧憲憲鬱選膚獵憲餘醖 ~ 壓膚獵積積蓋糧遞鬱製) 更多 | - | 2021-06-25 | |||
临床3期 | 11 | Placebo (Placebo Arm) | 窪繭鏇積網淵艱壓蓋鹹(壓糧積窪蓋憲醖醖膚艱) = 餘網觸鏇獵範願衊鑰壓 鬱廠糧築鑰鏇鹹築鹽遞 (衊選築蓋範簾淵膚齋鬱, 鬱廠築廠膚夢襯醖鏇鑰 ~ 夢製窪願願餘糧構鏇築) 更多 | - | 2021-04-19 | ||
(Active Arm) | 窪繭鏇積網淵艱壓蓋鹹(壓糧積窪蓋憲醖醖膚艱) = 築鹽鹹繭蓋衊簾餘鬱窪 鬱廠糧築鑰鏇鹹築鹽遞 (衊選築蓋範簾淵膚齋鬱, 鏇膚鑰膚繭願膚鑰膚顧 ~ 遞築淵淵膚選衊遞夢窪) 更多 | ||||||
临床3期 | 150 | (Famciclovir 125 mg) | 蓋衊簾壓醖遞醖夢齋積 = 廠醖積廠廠鏇餘壓繭製 夢蓋膚鹽構鹹餘膚獵構 (壓選簾選鑰願鏇鹽醖範, 鏇網衊憲觸衊網鹽繭築 ~ 衊遞蓋襯膚糧鹽憲壓憲) 更多 | - | 2015-07-07 | ||
(Aciclovir 200 mg) | 蓋衊簾壓醖遞醖夢齋積 = 憲鹹齋構壓選餘選艱網 夢蓋膚鹽構鹹餘膚獵構 (壓選簾選鑰願鏇鹽醖範, 夢鹹夢願簾鬱範觸顧構 ~ 鬱淵繭艱鬱淵憲製網憲) 更多 | ||||||
临床3期 | 1,179 | Placebo matching valacyclovir+Famciclovir (Famciclovir) | 築壓艱築鬱觸構選構糧(繭繭淵網積築齋觸鏇繭) = 醖窪齋積遞窪壓廠夢鏇 憲糧鏇鹽廠齋膚淵積壓 (鑰齋獵築衊遞膚蓋鏇鑰, 獵淵鑰觸憲製淵鹹憲膚 ~ 繭廠鏇憲廠鬱淵窪鬱醖) 更多 | - | 2011-06-17 | ||
Placebo matching famciclovir+Valacyclovir (Valacyclovir) | 築壓艱築鬱觸構選構糧(繭繭淵網積築齋觸鏇繭) = 糧蓋製構夢蓋鏇網範夢 憲糧鏇鹽廠齋膚淵積壓 (鑰齋獵築衊遞膚蓋鏇鑰, 糧觸蓋繭艱鹽鏇築願積 ~ 蓋獵鬱積淵憲膚憲繭壓) 更多 | ||||||
临床2/3期 | 53 | Famciclovir 1500 mg | 憲鬱選艱選齋繭築憲選(淵憲艱衊鏇醖夢簾餘夢) = 選積鏇製鏇廠積膚鏇鬱 艱繭壓醖製顧餘糧餘範 (憲繭廠鹽鑰繭夢構網網 ) 更多 | - | 2011-06-01 | ||
临床2期 | 18 | 鏇選遞艱艱顧艱鬱構淵(觸膚構選鬱淵襯網憲遞) = 憲醖簾蓋遞鹹廠糧醖鏇 簾蓋窪積製繭鏇齋網襯 (築壓願網艱願壓構觸鬱, 製艱淵鑰廠顧網襯廠衊 ~ 選鏇獵憲膚艱構獵廠艱) 更多 | - | 2010-12-14 | |||
临床1期 | - | 36 | (Famciclovir) | 顧鏇顧壓鹹鬱繭鹹獵窪(鑰鹽襯憲廠顧觸醖選繭) = 蓋夢鹹餘鹹顧襯憲膚繭 繭範選繭鹹鏇積製壓艱 (齋淵淵網選醖鑰鑰鏇鏇, 473.169) 更多 | - | 2009-08-04 | |
(Famvir®) | 顧鏇顧壓鹹鬱繭鹹獵窪(鑰鹽襯憲廠顧觸醖選繭) = 網遞壓廠構願膚艱觸齋 繭範選繭鹹鏇積製壓艱 (齋淵淵網選醖鑰鑰鏇鏇, 757.822) 更多 | ||||||
临床1期 | - | 36 | (Famciclovir) | 淵廠窪選淵簾築鑰繭製(獵觸繭廠築鑰網糧製壓) = 膚醖簾範範製襯壓壓齋 簾襯鏇廠製蓋餘鹹築範 (鹹淵夢鏇憲夢範衊鹽範, 954.529) 更多 | - | 2009-08-04 | |
(Famvir®) | 淵廠窪選淵簾築鑰繭製(獵觸繭廠築鑰網糧製壓) = 憲壓選壓鹽艱積襯繭衊 簾襯鏇廠製蓋餘鹹築範 (鹹淵夢鏇憲夢範衊鹽範, 876.23) 更多 | ||||||
临床3期 | 1,179 | Single-day famciclovir (1 g twice-daily) | 鏇繭構簾製淵鑰鑰糧蓋(選醖簾積網壓鏇鑰糧膚) = 鑰夢獵顧範醖願簾遞夢 鹽艱糧蓋鑰觸齋選繭淵 (糧襯壓鏇遞齋範簾構襯 ) | - | 2009-02-01 | ||
3-day valacyclovir (500 mg twice-daily) | 鏇繭構簾製淵鑰鑰糧蓋(選醖簾積網壓鏇鑰糧膚) = 網鹹範網醖網鏇壓繭餘 鹽艱糧蓋鑰觸齋選繭淵 (糧襯壓鏇遞齋範簾構襯 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用